TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05505877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR790+Tislelizumab
Description: BR790 will be administered orally, variable dose.~Tislelizumab will be administered as an intravenous infusion,fixed dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR790+Tislelizumab
Description: BR790 will be administered orally, variable dose.~Tislelizumab will be administered as an intravenous infusion,fixed dose.
Study: NCT05152173

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EN3835
Description: Participant will receive a maximum dose of up to1.8mg of EN3835 injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participant will receive a maximum dose of up to1.8mg of Placebo injection
Study: NCT06000423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 1300mg TXA taken three times per day for five days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills taken three times daily for five days.
Study: NCT05665933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACCEPTANCE AND COMMITMENT THERAPY-BASED PSYCOEDUCATION
Description: Total Duration: 6 Weeks Session Duration: 90 min Frequency: 1 day per week Number of People: 30
Study: NCT05796466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: How-to talk so kids will listen and listen so kids will talk
Description: The How-to Parenting Program focuses on how expectations, rules, and values are better communicated (vs. what rules ought to be). It includes skills related to the three components of authoritative parenting, namely affiliation, structure, and autonomy support. 1) Affiliation: Parents learn how to listen and respond to their children in a way that helps them feel accepted unconditionally. 2) Structure: Parents learn how to communicate expectations, give feedback, follow through, and use joint problem-solving in a factual, non-judgmental way. 3) Autonomy support: Parents learn how to validate emotions, encourage initiatives, and free children from roles. Finally, the How-to program can be endorsed by parents of various cultural backgrounds, as suggested by the large number (\> 30) of languages in which the material is translated. This advantage is crucial in ethnically diverse regions such as Canada.
Study: NCT05322148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free
Description: A number of studies have shown the benefit of both cyclosporine and steroids in managing dry eye. However, existing formulations of these products are challenged by either limited tolerability, a high out-of-pocket cost or both. Combination therapy with these agents in an advanced, more tolerable formulation have the potential to improve both tolerability and cost. However, the available formulation of preservative free Klarity CL (cyclosporine 0.1% and loteprednol 0.2% in a chondroitin sulfate vehicle) has not been studied rigorously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free
Description: A number of studies have shown the benefit of both cyclosporine and steroids in managing dry eye. However, existing formulations of these products are challenged by either limited tolerability, a high out-of-pocket cost or both. Combination therapy with these agents in an advanced, more tolerable formulation have the potential to improve both tolerability and cost. However, the available formulation of preservative free Klarity CL (cyclosporine 0.1% and loteprednol 0.2% in a chondroitin sulfate vehicle) has not been studied rigorously.
Study: NCT05929469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App
Description: Participants will receive an mHealth program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App
Description: Participants will receive an mHealth program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App
Description: Participants will receive an mHealth program.
Study: NCT05796466

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nobody's Perfect
Description: Nobody's Perfect is delivered in family resource centers across Canada to support parents of infants and preschoolers. Its focus is on developing parents' capacity to problem solve, providing child development information, and helping parents recognize their strengths and find their own positive ways to interact with their children. It thus does not teach specific parenting skills and does not suggest specific rules to put into practice in the home-environment.
Study: NCT05802407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Later-line therapy
Description: Another chemotherapy regimen, targeted therapy, or immunotherapy
Study: NCT05929469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App
Description: Participants will receive an mHealth program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App
Description: Participants will receive an mHealth program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App
Description: Participants will receive an mHealth program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fully Automated Kick-Off
Description: As an orientation to the study, participants will receive a fully automated kick-off session.
Study: NCT06014632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The study group will be given motor control exercises in addition to the program given to the control group.
Study: NCT05929469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fully Automated Kick-Off
Description: As an orientation to the study, participants will receive a fully automated kick-off session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fully Automated Kick-Off
Description: As an orientation to the study, participants will receive a fully automated kick-off session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Human-Enhanced Kick-Off
Description: As an orientation to the study, participants will receive a kick-off session that includes time with a study interventionist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Human-Enhanced Kick-Off
Description: As an orientation to the study, participants will receive a kick-off session that includes time with a study interventionist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Human-Enhanced Kick-Off
Description: As an orientation to the study, participants will receive a kick-off session that includes time with a study interventionist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check-In
Description: Participants will receive a check-in with a study interventionist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check-In
Description: Participants will receive a check-in with a study interventionist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Participants will receive counseling from a study interventionist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Participants will receive counseling from a study interventionist.
Study: NCT05756972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM8002
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion
Study: NCT03987841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated MBSR/DSME intervention
Description: Integrated mindfulness-based stress reduction/diabetes self-management education intervention. The intervention will comprise components of MBSR and DSME and will be delivered in a group setting with 8 weekly sessions. A trained masters-level interventionist will deliver the integrated intervention.
Study: NCT06014632

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive stretching, strengthening, core stabilization and educational content as usual care.
Study: NCT06544343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Monitoring
Description: Follow-up at outpatient clinic at 3 and 6 months from drug prescription Two remote consultations at 15 and 45 days from drug prescription

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: On site monitoring
Description: Follow-up at outpatient clinic at 3 and 6 months from drug prescription.
Study: NCT05210855

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT scan
Description: Scan with classic dose followed by ultra-low dose
Study: NCT05673226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surface disinfection with Organosilane
Description: Organosilane will be sprayed on the surfaces, using an atomizer. When the environment has been completely covered (i.e., when all surfaces and equipment have a slightly damp film), we will proceed with the second phase of the disinfection of all heavily touched surfaces. surfaces of the bed, with a microfiber cloth with organosilane.
Study: NCT06139757

Intervention type: DEVICE
Intervention: Oura ring
Description: Patient will wear Oura ring before and after embryo transfer. They will be blinded to sleep data during this period. Thus the intervention of wearing the ring to track sleep will not affect outcomes, but rather track the outcome of sleep.
Study: NCT06267885

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cannulated screws vs wagner's technique
Description: Fixation of fracture neck of femur by cannulated screws or wagner's technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cannulated screws vs wagner's technique
Description: Fixation of fracture neck of femur by cannulated screws or wagner's technique
Study: NCT06544343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: On site monitoring
Description: Follow-up at outpatient clinic at 3 and 6 months from drug prescription.
Study: NCT05635045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I 124-Evuzamitide
Description: Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I 124-Evuzamitide
Description: Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I 124-Evuzamitide
Description: Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging
Study: NCT04769466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LifeBio Memory
Description: LifeBio Memory is a digital reminiscence therapy platform designed to collect the life stories of older adults to generate personalized life storybooks that capture their unique narratives and social histories. Life story booklets, summaries, and materials are also developed as mechanisms for sharing this story and for staff to provide enhanced person-centered care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LifeBio Memory
Description: LifeBio Memory is a digital reminiscence therapy platform designed to collect the life stories of older adults to generate personalized life storybooks that capture their unique narratives and social histories. Life story booklets, summaries, and materials are also developed as mechanisms for sharing this story and for staff to provide enhanced person-centered care.
Study: NCT05561309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18034;Ropivacaine Hydrochloride Injection
Description: Drug: HR18034~Drug: Ropivacaine Hydrochloride Injection~Local nerve block of Ropivacaine Hydrochloride Injection to produce anesthesia for surgery and analgesia in postoperative pain management.~Other Name: Ropivacaine Hydrochloride Injection, 0.5% Injectable Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18034;Ropivacaine Hydrochloride Injection
Description: Drug: HR18034~Drug: Ropivacaine Hydrochloride Injection~Local nerve block of Ropivacaine Hydrochloride Injection to produce anesthesia for surgery and analgesia in postoperative pain management.~Other Name: Ropivacaine Hydrochloride Injection, 0.5% Injectable Solution
Study: NCT05845268

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor)
Description: Tislelizumab was added to long-course chemoradiotherapy (CRT) in LARC patients, CRT + concurrent tislelizumab was used in the Experimental arm, and CRT was used in the Active Comparator arm.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Long-course chemoradiation, without Tislelizumab (PD-1 inhibitor)
Description: Tislelizumab was added to long-course chemoradiotherapy (CRT) in LARC patients, CRT + concurrent tislelizumab was used in the Experimental arm, and CRT was used in the Active Comparator arm.
Study: NCT05887505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Oral supplementation of 576,000IU/day vitamin D3 in 3 consecutive days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral supplementation of placebo in 3 consecutive days.
Study: NCT05145387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transitioning Emotionally and Academically to Middle School Successfully (TEAMSS)
Description: Students randomized to TEAMSS will receive reading materials on transitioning to middle school and a a school tour with the middle school clinician (in 5th grade) and the TEAMSS group sessions (in 6th grade) delivered over 10 weeks. During the 10 weeks of TEAMSS, parents of students will attend two group meetings and clinicians will consult with at least one teacher (usually the advisory/homeroom teacher).
Study: NCT05077137

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Diptheria Vaccine
Description: tetanus and diphtheria toxoids
Study: NCT05561309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18034;Ropivacaine Hydrochloride Injection
Description: Drug: HR18034~Drug: Ropivacaine Hydrochloride Injection~Local nerve block of Ropivacaine Hydrochloride Injection to produce anesthesia for surgery and analgesia in postoperative pain management.~Other Name: Ropivacaine Hydrochloride Injection, 0.5% Injectable Solution
Study: NCT05037149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP707
Description: STP707 Powder for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP707
Description: STP707 Powder for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP707
Description: STP707 Powder for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP707
Description: STP707 Powder for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP707
Description: STP707 Powder for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP707
Description: STP707 Powder for Injection
Study: NCT05077137

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Boost Immunization
Description: trivalent inactivated polio vaccine
Study: NCT06433778

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT06584448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deuterium Metabolic Imaging with deuterated acetate tracer
Description: Deuterium Metabolic Imaging (DMI) is a method by which Magnetic Resonance Spectroscopy (MRS) is used to map the appearance of deuterium from a tracer source (e.g., deuterated acetate) in products of metabolism. In this case we will map the combination of glutamate and glutamine, called Glx, to serve as a tag to measure the brain's rate of acetate consumption. That is, the more deuterium appears in Glx, the more acetate that part of the brain consumes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deuterium Metabolic Imaging with deuterated acetate tracer
Description: Deuterium Metabolic Imaging (DMI) is a method by which Magnetic Resonance Spectroscopy (MRS) is used to map the appearance of deuterium from a tracer source (e.g., deuterated acetate) in products of metabolism. In this case we will map the combination of glutamate and glutamine, called Glx, to serve as a tag to measure the brain's rate of acetate consumption. That is, the more deuterium appears in Glx, the more acetate that part of the brain consumes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deuterium Metabolic Imaging with deuterated acetate tracer
Description: Deuterium Metabolic Imaging (DMI) is a method by which Magnetic Resonance Spectroscopy (MRS) is used to map the appearance of deuterium from a tracer source (e.g., deuterated acetate) in products of metabolism. In this case we will map the combination of glutamate and glutamine, called Glx, to serve as a tag to measure the brain's rate of acetate consumption. That is, the more deuterium appears in Glx, the more acetate that part of the brain consumes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deuterium Metabolic Imaging with deuterated acetate tracer
Description: Deuterium Metabolic Imaging (DMI) is a method by which Magnetic Resonance Spectroscopy (MRS) is used to map the appearance of deuterium from a tracer source (e.g., deuterated acetate) in products of metabolism. In this case we will map the combination of glutamate and glutamine, called Glx, to serve as a tag to measure the brain's rate of acetate consumption. That is, the more deuterium appears in Glx, the more acetate that part of the brain consumes.
Study: NCT06366633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-TIRELESS
Description: This is a self-administered web-based intervention that consists of 4 30-45-minute video sessions that teach mind-body skills, cognitive-behavioral strategies (e.g., reframing, pain and substance use urge surfing), activity pacing, acceptance and commitment skills, and psychoeducation on the association between substance use and pain. The program aims to increase patients' physical and emotional functioning and decrease pain intensity and maladaptive substance use behaviors.
Study: NCT06500819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B7-H3CART Dose (Intravenous)
Description: Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level -1 (DL-1) 0.3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 1 (DL1) 1 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 2 (DL2) 3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 2 (DL2) 3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 3 (DL3) 9 x 106 transduced T cells/kg
Study: NCT03909347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAN
Description: The study intervention, PLAN is a multifaceted intervention led by trained CHW. It consists of two main components: dementia literacy education and phone counseling with navigation assistance through (1) 1-hour visit for dementia literacy education and (2)monthly counseling with navigation assistance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The investigators will refer control group participants to participants' primary physicians for follow-up and provide an Alzheimer's Association brochure about signs of dementia and dementia treatment, which is publicly available in Korean.
Study: NCT05287126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Etrasimod tablet by mouth, once daily up to 52 weeks of treatment.
Study: NCT06571422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJ47156
Description: Monotherapy study: participate will recepit WJ47156 monotherpy with 3 dose groups; Combination therapy study: participate will recepit WJ47156 and other study drug if in the combination therapy period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001+Bevacizumab
Description: Participants in Cohort1 of combination therapy phase will receive WJ47156 plus toripalimab and bevacizumab.Toripalimab and bevacizumab are administered intravenously.
Study: NCT06580717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enavogliflozin 0.3mg
Description: Enavogliflozin 0.3mg, 1 tablet once a day, is prescribed for a period of 24 weeks.~Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of enavogliflozin 0.3 mg once daily or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: enavogliflozin Placebo
Description: A placebo pill identical to enavogliflozin, 1 tablet once a day, is prescribed for a period of 24 weeks.~Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of enavogliflozin 0.3 mg once daily or placebo.
Study: NCT05114096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celestone + placebo
Description: After the first intramuscular injection of Celestone, participants randomized to the Placebo Comparator group will receive 1 intramuscular injection of placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celestone + Celestone
Description: After the first intramuscular injection of Celestone, participants randomized to the Active Comparator group will receive 1 intramuscular injection of Celestone.
Study: NCT03777137

Intervention type: BEHAVIORAL
Intervention: TMS (Rapid2, Magstim Corp)
Description: Volunteers will take a telephone screening questionnaire and those meeting inclusion criteria will attend their first visit. Those signing the consent will have a T1 weighted MRI scan to localize sites in the brain to be stimulated with TMS. The subjects will then have four visits at intervals of two weeks; each visit will have a TMS intervention including SITE1, SITE2, SITE3, and SITE4. The sequence of the testing TMS four different visits (SITE1 to SITE4) will be randomly assigned among stimulation sites Medial Frontal (MF), Dorsal Lateral Frontal (DL), Primary motor cortex (M1) and Interparietal Sulcus (Sham) and counterbalanced across subjects (see Diagram below). During each of visits 2 to 5, each participant will undergo baseline Quantitative Sensory Testing (QST), followed by a TMS intervention, and then by repeat QST. QST will consist of pain thresholds for contact heat.
Study: NCT04968210

Intervention type: DRUG
Intervention: Hyperpolarized 13C-pyruvate
Description: Use of hyperpolarized 13C-pyruvate to assess metabolic remodeling in PAH
Study: NCT05364775

Intervention type: OTHER
Intervention: Focus group
Description: Focus group

Intervention type: OTHER
Intervention: Focus group
Description: Focus group